You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults

Article metrics

Article menu

This article has a correction. Please see:

Global health
Original research
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults

 

Online download statistics by month:

Online download statistics by month: April 2022 to October 2024

AbstractFullPdf
Apr 2022454645991563
May 202219161923199
Jun 202252553183
Jul 202236035185
Aug 2022770755123
Sep 202222421044
Oct 202217817441
Nov 202223120484
Dec 202216916442
Jan 202317917043
Feb 202314113119
Mar 202317716930
Apr 202310910536
May 202310710219
Jun 202313112218
Jul 20231059831
Aug 2023878735
Sep 202317616452
Oct 202311510219
Nov 202312511526
Dec 202311310029
Jan 2024907023
Feb 2024767320
Mar 2024737338
Apr 202420820226
May 2024727015
Jun 2024797218
Jul 2024888218
Aug 2024665716
Sep 2024745818
Oct 202416153
Total11326111482816